A noninferiority trial of cabozantinib (C) comparing 60mg vs 140mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC) Conference Paper uri icon

authors

  • Krajewska, J
  • Robinson, BG
  • Keam, B
  • Capdevila, J
  • Klochikhin, A
  • Gan, H
  • Kapiteijn, E
  • Elisei, R
  • Partyka, J
  • Borgman, AE
  • Schlumberger, M

publication date

  • 2018